Your Research, Realized.
Transform your early research into manufacturing readiness through expert guidance built for your stage.
Built to Move You from Discovery to Development
Early-phase programs deserve more than a starting point. Here’s how we help set you up for long-term success.
Research-Grade Material for Proof-of-Concept Studies
Blaze, our research-grade manufacturing offering, helps generate material for proof-of-concept studies, giving you insight into the manufacturability of your vector.
A Platform Built to Take You from Concept to Commercial
Utilizing a commercially viable platform like FUEL™ supports easier development and scale-up, reduces bridging studies, and minimizes risks to future approvals.
Robust Early Analytics that Build a Stronger Foundation
Partner with our experts to define and refine your AAV quality attributes early.
Proof-of-concept
Start with Blaze Research-Grade Production
Blaze is our research-grade AAV production offering at 1–40L, designed for early-stage discovery work like generating material for proof-of-concept studies and evaluating vector manufacturability.
Ready for growth
Advancing Beyond Discovery
Forge provides the same expert guidance and support for your program as it moves toward clinical production. With your proof-of-concept in place, we continue to support your journey with integrated AAV manufacturing services tailored to your next phase.
Forge Your Path
Let’s talk about how we can scale your AAV research today.
Hot off the Forge
-
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Building on an AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray’ gene therapy for patients living with retinitis pigmentosa and other blinding…
-
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership
The partnership will help advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with autosomal recessive deafness 8 (DFNB8).
-
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
New offering complements Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
-
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Strategic alliance will help advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne.